Skip to content
Trial Eligibility
Menu

Lupus Clinical Trials Recruiting in the US

100 studies for Lupus are recruiting at 632 US sites, according to ClinicalTrials.gov data processed .

Lupus is a long-term autoimmune disease in which the immune system attacks the body's own tissues and organs.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Top Lupus studies by number of US sites

Showing 30 studies, most US recruiting sites first.
  1. A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

    NCT06617325

    • Phase 3
    • Ages 16 years and older
    • Sex: All
    Recruiting sites
    62 US recruiting sites
  2. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    NCT03816345

    • Phase 1
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    40 US recruiting sites
  3. A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

    NCT07438496

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    38 US recruiting sites
  4. PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    NCT07611214

    • Phase 4
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    27 US recruiting sites
  5. Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

    NCT06133972

    • Phase 3
    • Ages 12 to 100 years
    • Sex: All
    Recruiting sites
    21 US recruiting sites
  6. An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

    NCT05835310

    • Phase 3
    • Ages 5 to 17 years
    • Sex: All
    Recruiting sites
    20 US recruiting sites
  7. The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

    NCT05538208

    • Phase 2
    • Ages 8 to 20 years
    • Sex: All
    Recruiting sites
    19 US recruiting sites
  8. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

    NCT06121297

    • Phase 1/2
    • Ages 12 to 65 years
    • Sex: All
    Recruiting sites
    18 US recruiting sites
  9. Lupus Landmark Study: A Prospective Registry and Biorepository

    NCT05934149

    • Observational
    • Ages 18 to 110 years
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  10. A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

    NCT06308978

    • Phase 1
    • Ages 12 to 70 years
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  11. A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

    NCT06557265

    • Phase 1/2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  12. A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

    NCT07085104

    • Phase 1
    • Ages 18 to 74 years
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  13. A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

    NCT07175285

    • Observational
    • Ages 16 years and older
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  14. A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

    NCT07409181

    • Phase 2
    • Ages 18 to 74 years
    • Sex: All
    Recruiting sites
    16 US recruiting sites
  15. VIBRANT: VIB4920 for Active Lupus Nephritis

    NCT05201469

    • Phase 2
    • Ages 18 years and older
    • Sex: All
    Recruiting sites
    15 US recruiting sites
  16. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

    NCT07260877

    • Phase 2
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    15 US recruiting sites
  17. A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

    NCT07430306

    • Phase 3
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    15 US recruiting sites
  18. A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

    NCT07355218

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    14 US recruiting sites
  19. A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

    NCT06570798

    • Phase 2
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    13 US recruiting sites
  20. A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

    NCT07201129

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    13 US recruiting sites
  21. A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

    NCT07332481

    • Phase 3
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  22. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

    NCT07570862

    • Phase 2
    • Ages 12 to 70 years
    • Sex: All
    Recruiting sites
    12 US recruiting sites
  23. Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

    NCT05799378

    • Phase 3
    • Ages 55 years and older
    • Sex: All
    Recruiting sites
    11 US recruiting sites
  24. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

    NCT07607964

    • Phase 1
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    11 US recruiting sites
  25. A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

    NCT06613360

    • Phase 1
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    10 US recruiting sites
  26. A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

    NCT06897930

    • Phase 1/2
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    10 US recruiting sites
  27. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

    NCT05039619

    • Phase 2
    • Ages 5 to 17 years
    • Sex: All
    Recruiting sites
    9 US recruiting sites
  28. A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

    NCT06925542

    • Phase 1
    • Ages 18 to 70 years
    • Sex: All
    Recruiting sites
    7 US recruiting sites
  29. Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    NCT07225387

    • Phase 4
    • Ages 18 to 80 years
    • Sex: All
    Recruiting sites
    7 US recruiting sites
  30. Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

    NCT07237659

    • Phase 1
    • Ages 18 to 75 years
    • Sex: All
    Recruiting sites
    7 US recruiting sites

By city

Lupus clinical trials by city

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Lupus clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.